(Press-News.org) A new method to cure HIV—by transplanting HIV-resistant stem cells from umbilical cord blood—has yielded long-term successful results, say scientists. The approach was successfully used to treat the “New York patient,” a middle-aged woman with leukemia and HIV who self-identifies as mixed race, who has been without HIV since 2017. Using stem cells from cord blood rather than from compatible adult donors, as has been done previously, increases the potential to cure HIV via stem cell transplantation in people of all racial backgrounds.
The researchers share the full results March 16 in the journal Cell; preliminary details on the case study were presented in February 2022 at the 29th annual Conference on Retroviruses and Opportunistic Infections.
“The HIV epidemic is racially diverse, and it’s exceedingly rare for persons of color or diverse race to find a sufficiently matched, unrelated adult donor,” says Yvonne Bryson of UCLA, who co-led the study with fellow pediatrician and infectious disease expert Deborah Persaud (@persaud_deborah) of the Johns Hopkins University School of Medicine. “Using cord blood cells broadens the opportunities for people of diverse ancestry who are living with HIV and require a transplant for other diseases to attain cures.”
Nearly 38 million people around the world live with HIV, and antiviral treatments, while effective, must be taken for life. The “Berlin patient” was the first person to be cured of HIV in 2009, and since then, two other men—the “London patient” and “Düsseldorf patient”—have also been rid of the virus. All three received stem cell transplants as part of their cancer treatments, and in all cases, the donor cells came from compatible or “matched” adults carrying two copies of the CCR5-delta32 mutation, a natural mutation that confers resistance to HIV by preventing the virus from entering and infecting cells.
Only around 1% of white people are homozygous for the CCR5-delta32 mutation and it is even rarer in other populations. This rarity limits the potential to transplant stem cells carrying the beneficial mutation into patients of color because stem cell transplants usually require a strong match between donor and recipient.
Knowing it would be almost impossible to find the New York patient a compatible adult donor with the mutation, the team instead transplanted CCR5-delta32/32-carrying stem cells from banked umbilical cord blood to try to cure both her cancer and HIV simultaneously. The patient received her transplant in 2017 at Weill Cornell Medicine thanks to a team of transplant specialists led by Drs. Jingmei Hsu and Koen van Besien. Her case was part of the NIH-sponsored International Maternal Adolescent AIDS Clinical Trials (IMPAACT) Network and was co-endorsed by the Adult AIDS Clinical Trials Network (ACTG).
The umbilical cord blood cells were infused alongside stem cells from one of the patient’s relatives to increase the procedure's chance of success. “With cord blood, you may not have as many cells, and it takes a little longer for them to populate the body after they're infused,” says Bryson. “Using a mixture of stem cells from a matched relative of the patient and cells from cord blood gives the cord blood cells a kick start.”
The transplant successfully put both the patient’s HIV and leukemia into remission, and this remission has now lasted more than four years. Thirty-seven months after the transplant, the patient was able to cease taking HIV antiviral medication. The doctors, who continue to monitor her, say she has now been HIV negative for more than 30 months since stopping antiviral treatment (at the time that the study was written, it had only been 18 months).
“Stem cell transplants with CCR5-delta32/32 cells offer a two-for-one cure for people living with HIV and blood cancers,” says Persaud. However, because of the invasiveness of the procedure, stem cell transplants (both with and without the mutation) are only considered for people who need a transplant for other reasons, and not for curing HIV in isolation; before a patient can undergo a stem cell transplant, they need to undergo chemotherapy or radiation therapy to destroy their existing immune system.
“This study is pointing to the really important role of having CCR5-delta32/32 cells as part of stem cell transplants for HIV patients, because all of the successful cures so far have been with this mutated cell population, and studies that transplanted new stem cells without this mutation have failed to cure HIV,” says Persaud. “If you're going to perform a transplant as a cancer treatment for someone with HIV, your priority should be to look for cells that are CCR5-delta32/32 because then you can potentially achieve remission for both their cancer and HIV.”
The authors emphasize that more effort needs to go into screening stem cell donors and donations for the CCR5-delta32 mutation. “With our protocol, we identified 300 cord blood units with this mutation so that if someone with HIV needed a transplant tomorrow, they would be available,” says Bryson, “but something needs to be done [on] an ongoing basis to search for these mutations, and support will be needed from communities and governments.”
This research was supported by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the AIDS Clinical Trials Group, the Weill Cornell Medicine-New Jersey Medical School Clinical Trials Unit, the PAVE Collaboratory, the Johns Hopkins CFAR, the IMPAACT Center subspecialty laboratory, the Miami CFAR at the University of Miami Miller School of Medicine, and the ACTG and IMPAACT Networks.
Cell, Hsu et al. ‘Possible HIV-1 Cure in a Woman Receiving CCR5 Δ32/Δ32 Haplo-Cord Stem Cell Transplant for Acute Myeloid Leukemia’, https://www.cell.com/cell/fulltext/S0092-8674(23)00173-3
Cell (@CellCellPress), the flagship journal of Cell Press, is a bimonthly journal that publishes findings of unusual significance in any area of experimental biology, including but not limited to cell biology, molecular biology, neuroscience, immunology, virology and microbiology, cancer, human genetics, systems biology, signaling, and disease mechanisms and therapeutics. Visit: http://www.cell.com/cell. To receive Cell Press media alerts, contact firstname.lastname@example.org.
The Ashaninka are the most numerous Indigenous people living in the rainforests of Peru and Brazil where they inhabit a crucial area between the Andes and sources of the Amazon River. And yet, despite the size of the population and their importance in the past and present, their genetic history has remained understudied.
Now a team of researchers reporting in the journal Current Biology on March 16 has analyzed the genomes of more than 50 individuals to clarify the group’s interactions with nearby South American regions, including Central America and the Caribbean. ...
Geneticists have written new chapters in the reconstruction of pre-colonial Americas history after using DNA from the indigenous Ashaninka people from Amazonian Peru. They have discovered previously unexpected levels of genetic variation in this group and uncovered a strong hint that these people were involved in a South-to-North migration that led to the transition from an archaic to ceramic culture in the Caribbean islands.
The dramatic impact of European colonisation during the second half of the last millennium has strongly influenced the genetic history of the Americas, making the reconstruction ...
About The Study: This survey study found that people with disabilities were more likely to report household employment loss and financial hardship during the initial COVID-19 pandemic, which are especially pronounced among racial and ethnic minority respondents. These findings suggest people with disabilities may be disproportionately affected by the initial pandemic and may require additional resources and policy strategies (e.g., training programs, workplace accommodations) as several labor markets adapt to the pandemic (e.g., shifting to remote working).
Authors: Kea Turner, Ph.D., M.P.H., M.A., of the H. Lee Moffitt Cancer Center ...
About The Study: In this study of 722,000 hospitalization episodes, patients with Alzheimer disease and related dementias (ADRD) had higher readmission rates and overall readmission and episode costs than their counterparts without ADRD. Hospitals may need to be better equipped to care for patients with ADRD, especially in the post-discharge period. Considering that any type of hospitalization may put patients with ADRD at a high risk of 30-day readmission, judicious preoperative assessment, postoperative discharge, and ...
Preterm infants do not get used to repeated pain in the way that full-term infants, children and adults do habituate to pain, finds a study led by UCL (University College London) researchers.
The authors of the new Current Biology paper say that if preterm infants have not yet developed the mechanism that enables people to get used to moderate pain, medical procedures in their first few weeks of life could potentially impact their development.
Lead author Dr Lorenzo Fabrizi (UCL Neuroscience, Physiology & Pharmacology) said: “The way that we can get used to things can be seen as the simplest example of behavioural and brain plasticity, and it is ...
Ikoma, Japan – The generation and maintenance of tissue boundaries are fundamental to the development of functional organs in both plants and animals. In general, tissue boundaries are initially set among primordial cells, and their shapes and arrangements are refined during subsequent organ growth. In this process, cell migration plays a curtail role for boundary refinement in animal systems, however, plant tissue lacks such cell fluidity due to its cell walls. Despite significant progress in understanding the initial patterning of tissue boundaries in several ...
A recent study makes it clear: Countries like Sweden that can link data from different areas - such as the labor market and health care - have a decisive advantage when it comes to setting targeted actions.
A research team from the Complexity Science Hub, together with scientists from Sweden, Denmark and the Netherlands, investigated the extent to which mental and somatic illnesses influence integration into the labor market and whether there is a difference here between refugee and Swedish-born young adults. "In total, we analyzed ...
Coal-fired power plants have been in place for a long time to meet the global demands for power generation. Needless to say, there are environmental and human health concerns to be addressed on this front. While there are ongoing efforts to transition to renewable energy resources, coal-fired power plants may not become obsolete just yet. Against this backdrop, it is pertinent to explore how the efficiency of these coal-fired boilers can be improved while mitigating their harmful effects on the environment, namely greenhouse gas emissions, acid rain, and photochemical smog generation, and the human health.
To this end, various ...
The rapidly-growing bottled water industry can undermine progress towards a key sustainable development goal: safe water for all, says a new United Nations report.
Based on an analysis of literature and data from 109 countries, the report says that in just five decades bottled water has developed into “a major and essentially standalone economic sector,” experiencing 73% growth from 2010 to 2020. And sales are expected to almost double by 2030, from US$ 270 billion to $500 billion.
(WASHINGTON, March 16, 2023) – While research has long established disparities in health outcomes among individuals living with sickle cell disease (SCD), few studies have quantified these gaps. A new study published in Blood Advances finds that the average life expectancy of publicly insured patients living with SCD is roughly 52.6 years. In contrast, the CDC reports that the average life expectancy in the United States is 73.5 years for men and 79.3 years for women, demonstrating the considerable ...